2008
DOI: 10.1345/aph.1l065
|View full text |Cite
|
Sign up to set email alerts
|

Maribavir: A Novel Antiviral Agent with Activity Against Cytomegalovirus

Abstract: Maribavir may be an option for treatment of ganciclovir-resistant CMV infections. Its bioavailability is greater than that of oral ganciclovir, but less than that of valganciclovir. No differences in pharmacokinetics were seen in renally impaired patients, although dialysis-dependent patients were not evaluated. Maribavir is not associated with hematologic toxicities; however, the high prevalence of taste disturbances may limit its tolerability.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
22
0

Year Published

2009
2009
2023
2023

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 50 publications
(22 citation statements)
references
References 36 publications
0
22
0
Order By: Relevance
“…Maribavir, a specific inhibitor of UL97 kinase activity, is currently being evaluated for approval as an antiviral agent against HCMV disease (10,11,47,48). Thus, the results presented here help establish a likely mechanism by which inhibition of UL97 may provide its therapeutic efficacy in patients (11,48).…”
Section: Discussionmentioning
confidence: 76%
“…Maribavir, a specific inhibitor of UL97 kinase activity, is currently being evaluated for approval as an antiviral agent against HCMV disease (10,11,47,48). Thus, the results presented here help establish a likely mechanism by which inhibition of UL97 may provide its therapeutic efficacy in patients (11,48).…”
Section: Discussionmentioning
confidence: 76%
“…The drugs used in the present study were obtained from various sources: the CDK inhibitors R25 (also known as Alsterpaullone) (Rechter et al, 2009) and R22 were provided by GPC Biotech AG (Martinsried, Germany), the CDK7-specific inhibitor LDC4297 was provided by Lead Discovery Centre GmbH (Dortmund, Germany), and maribavir (MBV), a specific inhibitor of the HCMV protein kinase pUL97 (Trofe et al, 2008;Chou et al, 2012), was purchased from Shanghai PI Chemicals Ltd (China). The compounds were dissolved in dimethyl sulfoxide (DMSO) and stored at À20 C according to the manufacturer's instructions.…”
Section: Methodsmentioning
confidence: 99%
“…MBV was developed in place of BDCRB, the development of which was abandoned since BDCRB is rapidly inactivated metabolically (61). MBV inhibits the replication of EBV and HCMV; the effects on HCMV involve the inhibition of enzymatic activity of the HCMV PK UL97, discovered initially through drug resistance caused by a mutation of the gene.…”
Section: Discussionmentioning
confidence: 99%